Repligen Corporation Q2 2025 Earnings Recap

RGEN Q2 2025 August 2, 2025

Get alerts when RGEN reports next quarter

Repligen Corporation delivered an outstanding Q2 2025 with 17% organic non-COVID growth, marking the highest growth rate since 2022, driven by robust performance across its biopharma and consumables segments.

Earnings Per Share Miss

$0.37 vs $0.40 est.

-7.5% surprise

Revenue Beat

182366000 vs 181819640 est.

+0.3% surprise

Market Reaction

1-Day +0.0%

5-Day -4.53%

30-Day +4.94%

See RGEN alongside your other holdings

Add to your portfolio — free

Key Takeaways

Biopharma revenue grew 20% year-over-year, with orders increasing over 20%, fueled by wins at large pharma clients.
Consumable revenue achieved a record high, surpassing 20% growth, while capital equipment revenue returned to growth in the high teens.
Orders consistently outpaced revenue for the eighth consecutive quarter, reflecting strong demand across diversified product offerings, particularly in filtration.
The company raised its revenue guidance for 2025 to a range of $715 million to $735 million, highlighting confidence in continued momentum amid macroeconomic challenges.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit RGEN on AllInvestView.

Next Q3 2025